drug_type
RELEVANT_DRUG
intervention_type
Genetically engineered TCR-T cell therapy (cellular therapy)
drug_description
Autologous, genetically engineered TCR-T cell therapy expressing an HLA-A*11:01–restricted T cell receptor specific for the KRAS G12V neoantigen; administered after lymphodepletion with a single IV infusion to recognize KRAS G12V peptides on tumor HLA-A*11:01, expand (with low-dose IL-2 support), and mediate cytotoxic killing of tumor cells in advanced solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an HLA-A*11:01–restricted TCR specific for the KRAS G12V neoantigen; after lymphodepletion and low-dose IL-2 support, the infused cells recognize KRAS G12V peptides presented on tumor HLA-A*11:01, expand, and mediate cytotoxic killing of mutant KRAS–expressing tumor cells.
drug_name
NW-301V
nct_id_drug_ref
NCT06484556